People with tough-to-treat triple negative breast cancer, whose tumors also don’t allow for double-strand DNA repair, fare better when treated with a common adjuvant breast cancer chemotherapy combination, according to results from a SWOG clinical trial.
Published in Annals of Oncology, the trial results show that a well-established drug combination – adjuvant doxorubicin and cyclophosphamide (AC) chemotherapy – works well in this patient population. The results also show the value of collecting and preserving cancer tumor tissue. Priyanka Sharma, MD, of University of Kansas Cancer Center, and her team used nearly 20-year-old tumor samples stored in SWOG’s biospecimen bank to conduct their analysis.
“Banking tissue in cancer research is a smart investment,” Sharma said. “Tissue collected for one research study can be used for others, creating value for patients, investigators, and for the public who funds our SWOG research.”
Sharma is a associate professor of medicine and a breast cancer oncologist at University of Kansas Cancer Center, and the vice chair of the breast committee for SWOG, the cancer clinical trials group that is part of the National Cancer Institute’s (NCI) publicly funded National Clinical Trials Network (NCTN). Sharma has spent over a decade conducting research to better understand
Article originally posted at